Bristol Myers Squibb Company (NYSE:BMY) Receives Consensus Rating of “Hold” from Analysts

Bristol Myers Squibb Company (NYSE:BMY) has received a consensus recommendation of “Hold” from the nineteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eight have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $61.3125.

A number of analysts have weighed in on BMY shares. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Barclays initiated coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Finally, Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target on the stock.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.05% of the company’s stock.

Institutional Trading of Bristol Myers Squibb

Several institutional investors have recently modified their holdings of the business. Westshore Wealth LLC bought a new stake in shares of Bristol Myers Squibb in the first quarter worth $477,000. Summit Financial Wealth Advisors LLC boosted its holdings in Bristol Myers Squibb by 13.5% in the first quarter. Summit Financial Wealth Advisors LLC now owns 13,050 shares of the biopharmaceutical company’s stock valued at $791,000 after acquiring an additional 1,549 shares during the last quarter. Axiom Investment Management LLC bought a new stake in Bristol Myers Squibb in the first quarter valued at approximately $84,000. Summitry LLC boosted its holdings in Bristol Myers Squibb by 14.4% in the first quarter. Summitry LLC now owns 7,574 shares of the biopharmaceutical company’s stock valued at $459,000 after acquiring an additional 954 shares during the last quarter. Finally, WNY Asset Management LLC bought a new stake in Bristol Myers Squibb in the first quarter valued at approximately $790,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $57.63 on Friday. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The business’s 50-day moving average price is $58.42 and its two-hundred day moving average price is $56.18. The stock has a market cap of $117.68 billion, a PE ratio of 16.19, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts expect that Bristol Myers Squibb will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 70.79%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.